MultiCell Technologies Announces Milestone Patent Issued by European Patent Office on Treatments for Autoimmune Diseases.Newly Granted Patent Covers Company's Immune-Based Therapeutics to Target MS, Diabetes and other Unmet Medical Needs SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- MultiCell Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :MCET MCET Massachusetts Corporation for Educational Telecommunications MCET Maryland Center for Environmental Training MCET Micro-Computer Electronics Technology MCET Michigan Consumer Evaluation Team, Inc ), developing first-in-class drugs based on advanced immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. modulation and other proprietary technologies, today announced that the European Patent Office has granted the Company a key patent covering its next-generation technology targeting multibillion-dollar medical marketplace segments, including a range of serious autoimmune disorders Autoimmune Disorders Definition Autoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction. such as diabetes and multiple sclerosis. The patent issuance is a significant validation of the Company's business strategy to obtain broad, worldwide protection of its advanced immune modulation technologies and intellectual property. The Company recently announced that its IP portfolio crossed the key threshold of more than 50 issued or pending patents. The patent, "Compositions for Treating Autoimmune Disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma ," leverages MultiCell's proprietary platform technologies in the science of modulating the human immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. to treat a range of serious diseases. "We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We have already advanced our products into human clinical trials where researchers have reported extremely encouraging results showing the efficacy of our drug candidates to treat patients with MS and other conditions that desperately need new and substantially better therapeutic options." MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. The newly issued patent is related to compositions for the effective endocytic presentation of immunosuppressive Immunosuppressive Any agent that suppresses the immune response of an individual. Mentioned in: Antirheumatic Drugs, Graft-vs.-Host Disease, Immunosuppressant Drugs immunosuppressive 1. pertaining to or inducing immunosuppression. 2. factors that are useful for the treatment of various disorders, such as autoimmune disorders. The Company's technology platforms include Toll-like Receptor Toll-like receptors (TLRs) are a class of single membrane-spanning non-catalytic receptors that recognize structurally conserved molecules derived from microbes once they have breached physical barriers such as the skin or intestinal tract mucosa, and activate immune cell signaling and T-cell targeting to modulate To insert a data signal into a carrier wave or direct current. See modulation. both the innate and adaptive immune systems
About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html. Forward-Looking Statements Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could" and "would." Examples of such forward-looking statements include statements regarding plans to develop new drug candidates, plans to expand intellectual property holdings, the ability of MultiCell to accelerate any of its therapeutic programs, or the ability of MultiCell to commercialize any drug candidates. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statements include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion